Fibromyalgia syndrome (FMS) Nervous System Diseases Other soft tissue disorders, not elsewhere classified
Conditions
Interventions
The subjects will be randomised into a microcurrent group and a placebo group. They all will receive two 30 minute sessions a week for three weeks. They will ask to attend all sessions but can leave t
frequency between 30 and 40 Hz
two channels). The researcher chooses the electrode position on the basis of these indicators and using the research team?s predefined protocol, which have standardized the electrode positions. The s
Sponsors
University Rovira i Virgili (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients of either sex diagnosed with FMS in accordance with the American College of Rheumatology?s criteria (final age range at end of recruitment was 33-71 years) 2. Recruited from the Catalan Association for People Affected by FMS
Exclusion criteria
Exclusion criteria: 1. Suffering from a multiple organic disease 2. Pregnant 3. Patients with a demand-type cardiac pacemaker 4. Receiving physiotherapy treatment or having finished treatment in the previous month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibromyalgia Impact Questionnaire (Cuestionario de Impacto de la Fibromialgia [CIF]) The values of the CIF are between 0 and 100, 0 being the best state of health and 100 the worst. CIF will be assessed at the start of treatment (CIF0), at the end of the treatment (CIF1) and at one month after treatment (CIF2). | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale (VAS) (0 = no pain, 10 = unbearable pain), assessed at the start of treatment (VAS0), at end of the treatment (VAS1) and at one month after treatment (VAS2). | — |
Countries
Spain
Outcome results
None listed